Related Experiment Video
Updated: May 1, 2026
11:19
Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
Published on: October 9, 2016
16.1K
Genetic Interactions of STAT3 and Anticancer Drug Development
1Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. bfang@mdanderson.org.
Cancers
|March 26, 2014
Summary
Signal transducer and activator of transcription 3 (STAT3) is a key target in cancer therapy. Understanding STAT3
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Signal transducer and activator of transcription 3 (STAT3) is crucial in cancer development and progression.
- STAT3 inhibitors are investigated as cancer therapeutics, but clinical translation faces challenges.
- Lack of efficacy in anticancer drug development often stems from pathway redundancy in cancer cells.
Purpose of the Study:
- To review the functional regulation of STAT3 activity.
- To explore interactions between STAT3 and other cancer-related pathways like RAS and EGFR.
- To elucidate mechanisms influencing STAT3 inhibitor efficacy for improved cancer treatments.
Main Methods:
- Literature review of STAT3 function and its interactions with key cancer pathways.
- Analysis of molecular mechanisms modulating STAT3 inhibitor efficacy.
- Exploration of genetic interactions to overcome resistance to targeted therapies.
Main Results:
- STAT3 pathway interactions, including with RAS and epidermal growth factor receptor (EGFR), impact cancer cell survival.
- Redundant signaling pathways contribute to resistance against single-target STAT3 inhibitors.
- Understanding these interactions is key to improving therapeutic strategies.
Conclusions:
- Targeting STAT3 alone may be insufficient due to complex pathway crosstalk.
- Investigating genetic interactions of STAT3 with pathways like RAS and EGFR can reveal resistance mechanisms.
- This knowledge can guide the development of more effective anticancer agents and combination therapies.
More Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
03:03mTOR Signaling and Cancer Progression
1.5K
1.5K
01:20The JAK-STAT Signaling Pathway
10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.2K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
2.6K
2.6K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81